Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients

This randomized, double-blind, placebo-controlled cross-over trial evaluated the efficacy of 500 mg of oral resveratrol twice daily for four weeks in pre-hypertensive and stage-1-hypertensive patients. While the treatment significantly increased nitric oxide production compared to the placebo, it failed to demonstrate a statistically superior reduction in systolic or diastolic blood pressure.

Source : https://www.nature.com/articles/s41598-025-17305-6